Free Trial

Ocugen (OCGN) Competitors

Ocugen logo
$1.02 +0.02 (+2.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 -0.01 (-0.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OCGN vs. MRNA, PFE, WVE, AMPH, GPCR, COGT, NTLA, ARDX, AUPH, and VERV

Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Moderna (MRNA), Pfizer (PFE), WAVE Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), Structure Therapeutics (GPCR), Cogent Biosciences (COGT), Intellia Therapeutics (NTLA), Ardelyx (ARDX), Aurinia Pharmaceuticals (AUPH), and Verve Therapeutics (VERV). These companies are all part of the "medical" sector.

Ocugen vs. Its Competitors

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Ocugen has higher earnings, but lower revenue than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocugen$4.05M73.55-$54.05M-$0.19-5.37
Moderna$3.24B3.74-$3.56B-$8.73-3.58

Ocugen presently has a consensus price target of $6.00, indicating a potential upside of 488.24%. Moderna has a consensus price target of $46.61, indicating a potential upside of 49.11%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts plainly believe Ocugen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Moderna
4 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.04

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.4% of Ocugen shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ocugen has a beta of 4.18, indicating that its share price is 318% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Moderna has a net margin of -105.67% compared to Ocugen's net margin of -1,271.12%. Moderna's return on equity of -28.69% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocugen-1,271.12% -223.00% -92.20%
Moderna -105.67%-28.69%-21.94%

In the previous week, Moderna had 15 more articles in the media than Ocugen. MarketBeat recorded 21 mentions for Moderna and 6 mentions for Ocugen. Ocugen's average media sentiment score of 0.85 beat Moderna's score of 0.59 indicating that Ocugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocugen
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
7 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Moderna beats Ocugen on 9 of the 16 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCGN vs. The Competition

MetricOcugenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$292.03M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-5.378.2821.0120.09
Price / Sales73.55303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book10.207.678.125.65
Net Income-$54.05M-$55.28M$3.25B$257.91M
7 Day Performance-10.53%2.50%0.97%2.09%
1 Month Performance-6.42%11.70%7.36%11.13%
1 Year Performance-37.61%4.89%31.31%18.40%

Ocugen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCGN
Ocugen
1.2758 of 5 stars
$1.02
+2.0%
$6.00
+488.2%
-45.4%$292.03M$4.05M-5.3780News Coverage
MRNA
Moderna
4.2835 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-74.0%$11.56B$3.24B-3.425,800Trending News
Options Volume
Analyst Revision
PFE
Pfizer
4.9618 of 5 stars
$25.23
-0.6%
$28.55
+13.2%
-18.1%$143.44B$63.63B18.2881,000Trending News
WVE
WAVE Life Sciences
4.5817 of 5 stars
$7.06
+1.6%
$20.50
+190.4%
+35.5%$1.10B$108.30M-8.40240Analyst Forecast
AMPH
Amphastar Pharmaceuticals
4.3171 of 5 stars
$22.86
-1.5%
$32.33
+41.4%
-45.0%$1.08B$731.97M8.282,028
GPCR
Structure Therapeutics
2.9436 of 5 stars
$18.73
-8.1%
$76.17
+306.7%
-49.1%$1.07BN/A-21.53136
COGT
Cogent Biosciences
3.5461 of 5 stars
$9.35
+23.4%
$16.33
+74.7%
+35.9%$1.06BN/A-5.0880Trending News
Analyst Forecast
Analyst Revision
Gap Up
High Trading Volume
NTLA
Intellia Therapeutics
4.4128 of 5 stars
$10.25
-4.6%
$33.37
+225.5%
-56.8%$1.06B$57.88M-1.96600Gap Up
ARDX
Ardelyx
4.1637 of 5 stars
$4.35
+1.9%
$10.89
+150.3%
-21.4%$1.04B$333.61M-19.7790Analyst Revision
AUPH
Aurinia Pharmaceuticals
3.2887 of 5 stars
$7.47
-1.6%
$11.50
+53.9%
+55.3%$1.01B$235.13M26.68300Positive News
VERV
Verve Therapeutics
2.8995 of 5 stars
$11.16
-1.1%
$14.57
+30.6%
+45.8%$994.80M$32.33M-5.29110

Related Companies and Tools


This page (NASDAQ:OCGN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners